{{Drugbox
| IUPAC_name = 1-(8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methylpiperazine
| image = Clorotepine.svg
| width = 225px
| tradename = Clotepin, Clopiben
| CAS_number = 13448-22-1
| CAS_supplemental = <br />4789-68-8 ([[maleate]])<br />42505-79-3 ([[mesylate]])
| ATC_prefix = None
| ATC_suffix = 
| UNII = E65W20MU7A
| PubChem = 1238
| ChemSpiderID = 1201
| ChEMBL = 64249
| C = 19 | H = 21 | Cl = 1 | N = 2 | S = 1
| molecular_weight = 344.901 g/mol
| SMILES = Clc4cc2c(Sc1ccccc1CC2N3CCN(C)CC3)cc4
| synonyms = Octoclothepin; Octoclothepine; VUFB-6281; VUFB-10030
| StdInChI = 1S/C19H21ClN2S/c1-21-8-10-22(11-9-21)17-12-14-4-2-3-5-18(14)23-19-7-6-15(20)13-16(17)19/h2-7,13,17H,8-12H2,1H3
| StdInChIKey = XRYLGRGAWQSVQW-UHFFFAOYSA-N
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]
}}

'''Clorotepine''' ({{abbrlink|INN|International Nonproprietary Name}}; brand names '''Clotepin''', '''Clopiben'''), also known as '''octoclothepin''' or '''octoclothepine''', is an [[antipsychotic]] of the [[tricyclic]] group which was derived from [[perathiepin]] in 1965 and marketed in the [[Czech Republic]] by Spofa in or around 1971 for the treatment of [[schizophrenic]] [[psychosis]].<ref name="Index nominum 2000: international drug directory">{{cite book | title = Index nominum 2000: international drug directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA265 | accessdate = 26 November 2011 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | pages = 265}}</ref><ref name="GanellinTriggle1997">{{cite book | author1 = C. R Ganellin | author2 = D. J Triggle | author3 = F.. Macdonald | title = Dictionary of pharmacological agents | url = https://books.google.com/books?id=DeX7jgInYFMC&pg=PA500 |  accessdate = 26 November 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | pages = 500}}</ref><ref name="pmid6893891">{{cite journal |vauthors=Metysová J, Metys J, Dlabac A, Kazdová E, Valchár M | title = Pharmacological properties of a potent neuroleptic drug octoclothepin | journal = Acta Biologica et Medica Germanica | volume = 39 | issue = 6 | pages = 723–40 | year = 1980 | pmid = 6893891 | doi = | url = }}</ref><ref name="Cain1971">{{cite book | author = Cornelius K. Cain | title = Annual Reports in Medicinal Chemistry | url = https://books.google.com/books?id=dBGM4WSV_YEC&pg=PA5 | accessdate = 26 November 2011 | date = 1 January 1971 | publisher = Academic Press | isbn = 978-0-12-040506-0 | pages = 5}}</ref><ref name="Protiva2010">{{cite journal|last1=Protiva|first1=M.|title=ChemInform Abstract: Fifty Years in Chemical Drug Research|journal=ChemInform|volume=23|issue=9|year=2010|pages=no–no|issn=09317597|doi=10.1002/chin.199209338}}</ref><ref name="pmid5576292">{{cite journal | vauthors = Melich H | title = [Clotepin] | language = Czech | journal = Cas. Lek. Cesk. | volume = 110 | issue = 17 | pages = 404–5 | year = 1971 | pmid = 5576292 | doi = | url = }}</ref>

Clorotepine is known to have high [[affinity (pharmacology)|affinity]] for the [[dopamine receptor|dopamine]] [[D1 receptor|D<sub>1</sub>]],<ref name="pmid11784139">{{cite journal |vauthors=Campiani G, Butini S, Gemma S | title = Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies | journal = Journal of Medicinal Chemistry | volume = 45 | issue = 2 | pages = 344–59 |date=January 2002 | pmid = 11784139 | doi = 10.1021/jm010982y|display-authors=etal}}</ref> [[D2 receptor|D<sub>2</sub>]],<ref name="pmid16135699">{{cite journal |vauthors=Burstein ES, Ma J, Wong S | title = Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 3 | pages = 1278–87 |date=December 2005 | pmid = 16135699 | doi = 10.1124/jpet.105.092155 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=16135699|display-authors=etal}}</ref> [[D3 receptor|D<sub>3</sub>]],<ref name="pmid16135699" /> and [[D4 receptor|D<sub>4</sub> receptor]]s,<ref name="pmid16135699" /> the [[serotonin receptor|serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub>]],<ref name="pmid11784139" /> [[5-HT2B receptor|5-HT<sub>2B</sub>]],<ref name="pmid1676758">{{cite journal |vauthors=Bøgesø KP, Liljefors T, Arnt J, Hyttel J, Pedersen H | title = Octoclothepin enantiomers. A reinvestigation of their biochemical and pharmacological activity in relation to a new receptor-interaction model for dopamine D-2 receptor antagonists | journal = Journal of Medicinal Chemistry | volume = 34 | issue = 7 | pages = 2023–30 |date=July 1991 | pmid = 1676758 | doi = 10.1021/jm00111a015| url = }}</ref> [[5-HT2C receptor|5-HT<sub>2C</sub>]],<ref name="pmid1676758" /> [[5-HT6 receptor|5-HT<sub>6</sub>]],<ref name="pmid7908055">{{cite journal |vauthors=Roth BL, Craigo SC, Choudhary MS | title = Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 268 | issue = 3 | pages = 1403–10 |date=March 1994 | pmid = 7908055 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7908055|display-authors=etal}}</ref> and [[5-HT7 receptor|5-HT<sub>7</sub> receptor]]s,<ref name="pmid7908055" /> the [[alpha-1A adrenergic receptor|α<sub>1A</sub>-]],<ref name="pmid20857909">{{cite journal |vauthors=Kristensen JL, Püschl A, Jensen M | title = Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for α(1)-adrenoceptors | journal = Journal of Medicinal Chemistry | volume = 53 | issue = 19 | pages = 7021–34 |date=October 2010 | pmid = 20857909 | doi = 10.1021/jm100652h | url = https://dx.doi.org/10.1021/jm100652h|display-authors=etal}}</ref> [[alpha-1B adrenergic receptor|α<sub>1B</sub>-]],<ref name="pmid20857909" /> and [[alpha-1D adrenergic receptor|α<sub>1D</sub>-adrenergic receptor]]s,<ref name="pmid20857909" /> and the [[histamine receptor|histamine]] [[H1 receptor|H<sub>1</sub>]] [[receptor (biochemistry)|receptor]]s,<ref name="pmid15947036">{{cite journal |vauthors=Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R | title = Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 314 | issue = 3 | pages = 1310–21 |date=September 2005 | pmid = 15947036 | doi = 10.1124/jpet.105.087965 | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=15947036}}</ref> where it has been it has been confirmed to act as an [[receptor antagonist|antagonist]] (or [[inverse agonist]]) at most sites (and likely is as such at all of them based on [[structure–activity relationships]]), and it also blocks the [[reuptake]] of [[norepinephrine]] via [[reuptake inhibitor|inhibition]] of the [[norepinephrine transporter]].<ref name="pmid2892932">{{cite journal |vauthors=Liljefors T, Bøgesø KP | title = Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(−)-tefludazine, (S)-(+)- and (R)-(−)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition | journal = Journal of Medicinal Chemistry | volume = 31 | issue = 2 | pages = 306–12 |date=February 1988 | pmid = 2892932 | doi = 10.1021/jm00397a006| url = }}</ref>

Due to its very potent activity at the D<sub>2</sub> receptor, along with [[tefludazine]], clorotepine was used as the basis for developing a [[3-dimensional]] (3D) [[pharmacophore]] for D<sub>2</sub> receptor antagonists.<ref name="Krogsgaard-LarsenLiljefors2002">{{cite book | author1 = Povl Krogsgaard-Larsen | author2 = Tommy Liljefors | author3 = Ulf Madsen | title = Textbook of drug design and discovery | url = https://books.google.com/books?id=EL-UI6t8omQC&pg=PA108 | accessdate = 26 November 2011 | date = 25 July 2002 | publisher = CRC Press | isbn = 978-0-415-28288-8 | page = 108}}</ref>

==See also==
* [[Metitepine]]
* [[Perathiepin]]

==References==
{{Reflist}}

{{Antipsychotics}}
{{Sedatives}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Antipsychotics]]
[[Category:Chloroarenes]]
[[Category:Dibenzothiepines]]
[[Category:Piperazines]]
[[Category:Sedatives]]